High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood

被引:6
作者
Krueger, Kimberly [1 ]
Mayer, Zsuzsanna [1 ]
Gerckens, Miriam [2 ]
Boeck, Stefan [2 ]
Luppa, Peter [3 ]
Holdenrieder, Stefan [1 ]
机构
[1] Tech Univ Munich, German Heart Ctr Munich, Munich Biomarker Res Ctr, Inst Lab Med, D-80636 Munich, Germany
[2] Univ Hosp Munich Grosshadern, Dept Internal Med 3, D-81377 Munich, Germany
[3] Tech Univ Munich, Dept Clin Chem, Univ Hosp, D-81675 Munich, Germany
关键词
PD-1; PD-L1; PD-L2; analytical validation; ELISA; EXPRESSION; BIOMARKER; TOLERANCE; MECHANISM; RECEPTOR; LIGANDS; MEMBER; CELLS;
D O I
10.3390/biomedicines10102405
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Programmed death-1 receptor PD-1(CD279) and its corresponding ligands PD-L1(CD274, B7-H1) and PD-L2(CD273, B7-DC) play important roles in physiological immune tolerance and for immune escape in cancer disease. Hence, the establishment and analytical validation of a novel enzyme-linked immunosorbent assay (ELISA) to measure soluble PD-1, PD-L1 and PD-L2 in blood samples according to high quality standards is required. Antibody pairs were used to establish novel highly sensitive ELISAs for all three markers on an open electrochemiluminescence Quickplex platform. Analytical validation comprised intra- and interassay imprecision, limit of quantification, dilution linearity, material comparison and analytical selectivity testing. The methods demonstrated a broad dynamic range and precise measurements down to the pg/mL range. The coefficient of variation (CV) during the intra-assay imprecision measurements with three patient pools did not exceed 10% for all three assays (PD-1: 6.4%, 6.5%, 7.8%, PD-L1: 7.1%, 4.2%, 6.8%; PD-L2: 4.5%, 10.0%, 9.9%). Dilution linearity experiments in both buffer and heparin plasma displayed good linearity. Selectivity was shown for each marker in titration cross-reactivity experiments up to concentrations of at least 15 ng/mL of these, possibly confounding other markers. Soluble PD-1, PD-L1 and PD-L2 can be measured highly sensitively in serum and plasma and can safely be applied to clinical study settings.
引用
收藏
页数:13
相关论文
共 28 条
  • [21] PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
    Patel, Sandip Pravin
    Kurzrock, Razelle
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (04) : 847 - 856
  • [22] Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
    Patsoukis, Nikolaos
    Brown, Julia
    Petkova, Victoria
    Liu, Fang
    Li, Lequn
    Boussiotis, Vassiliki A.
    [J]. SCIENCE SIGNALING, 2012, 5 (230)
  • [23] Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Samstein, Robert M.
    Lee, Chung-Han
    Shoushtari, Alexander N.
    Hellmann, Matthew D.
    Shen, Ronglai
    Janjigian, Yelena Y.
    Barron, David A.
    Zehir, Ahmet
    Jordan, Emmet J.
    Omuro, Antonio
    Kaley, Thomas J.
    Kendall, Sviatoslav M.
    Motzer, Robert J.
    Hakimi, A. Ari
    Voss, Martin H.
    Russo, Paul
    Rosenberg, Jonathan
    Iyer, Gopa
    Bochner, Bernard H.
    Bajorin, Dean F.
    Al-Ahmadie, Hikmat A.
    Chaft, Jamie E.
    Rudin, Charles M.
    Riely, Gregory J.
    Baxi, Shrujal
    Ho, Alan L.
    Wong, Richard J.
    Pfister, David G.
    Wolchok, Jedd D.
    Barker, Christopher A.
    Gutin, Philip H.
    Brennan, Cameron W.
    Tabar, Viviane
    Mellinghoff, Ingo K.
    DeAngelis, Lisa M.
    Ariyan, Charlotte E.
    Lee, Nancy
    Tap, William D.
    Gounder, Mrinal M.
    D'Angelo, Sandra P.
    Saltz, Leonard
    Stadler, Zsofia K.
    Scher, Howard I.
    Baselga, Jose
    Razavi, Pedram
    Klebanoff, Christopher A.
    Yaeger, Rona
    Segal, Neil H.
    Ku, Geoffrey Y.
    DeMatteo, Ronald P.
    [J]. NATURE GENETICS, 2019, 51 (02) : 202 - +
  • [24] Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
    Schadendorf, Dirk
    Hodi, F. Stephen
    Robert, Caroline
    Weber, Jeffrey S.
    Margolin, Kim
    Hamid, Omid
    Patt, Debra
    Chen, Tai-Tsang
    Berman, David M.
    Wolchok, Jedd D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1889 - U48
  • [25] Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
    Schildberg, Frank A.
    Klein, Sarah R.
    Freeman, Gordon J.
    Sharpe, Arlene H.
    [J]. IMMUNITY, 2016, 44 (05) : 955 - 972
  • [26] Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
    Sharma, Padmanee
    Hu-Lieskovan, Siwen
    Wargo, Jennifer A.
    Ribas, Antoni
    [J]. CELL, 2017, 168 (04) : 707 - 723
  • [27] Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity
    Sun, Linlin
    Li, Chia-Wei
    Chung, Ezra M.
    Yang, Riyao
    Kim, Yong-Soo
    Park, Andrew H.
    Lai, Yun-Ju
    Yang, Yi
    Wang, Yu-Han
    Liu, Jielin
    Qiu, Yufan
    Khoo, Kay-Hooi
    Yao, Jun
    Hsu, Jennifer L.
    Cha, Jong-Ho
    Chan, Li-Chuan
    Hsu, Jung-Mao
    Lee, Heng-Huan
    Yoo, Stephen S.
    Hung, Mien-Chie
    [J]. CANCER RESEARCH, 2020, 80 (11) : 2298 - 2310
  • [28] Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
    Zhang, Min
    Yang, Jingwen
    Hua, Wenjing
    Li, Zhong
    Xu, Zenghui
    Qian, Qijun
    [J]. FRONTIERS OF MEDICINE, 2019, 13 (01) : 32 - 44